FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003146718> ?p ?o ?g. }

• W2003146718 endingPage "362" @default.
• W2003146718 startingPage "355" @default.
• W2003146718 abstract "<b><i>Background:</i></b> Aspirin (acetylsalicylic acid, ASA) is the treatment of choice for prevention of vascular events in symptomatic steno-occlusive cerebrovascular disease (CVD). Cerebral revascularization using standard extracranial-intracranial (EC-IC) bypass surgery may be used to revert hemodynamic compromise. Aspirin is prescribed as standard medication in order to avoid bypass failure. Accumulating evidence of an increased risk of major adverse clinical events led to this study, in which we aimed to assess the prevalence of aspirin resistance and prothrombotic disorders among patients scheduled for EC-IC bypass surgery, and the effectiveness of aspirin dose escalation. <b><i>Methods:</i></b> We prospectively screened patients with circumscribed high-grade stenosis or occlusion of brain-supplying vessels fulfilling the hemodynamic criteria for EC-IC bypass surgery for aspirin resistance using a platelet function analyzer (PFA-100®) test. We also determined their smoking habits and screened for prothrombotic disorders and comorbidities. The patients were divided into 2 major groups: group A had atherosclerotic steno-occlusive CVD and group B consisted of patients with nonatherosclerotic steno-occlusive CVD (moyamoya disease) and a subgroup of pediatric moyamoya patients (pediatric subgroup). Bypass patency was documented via digital subtraction angiography. Standard initial ASA dose applied was 100 mg/day. In cases of aspirin resistance, doses were increased and the PFA-100 test was repeated. <b><i>Results:</i></b> A total of 56 patients were included over a time period of 6 months. In group A (n = 25), we found a ratio of 40% of patients with primary resistance to aspirin 100 mg/day. In contrast, in group B (n = 25), only 20% of the patients were resistant to aspirin 100 mg/day; in the pediatric population (n = 6), there was no primary aspirin resistance. After a dose escalation to 300 mg/day, the ratio of aspirin resistance was reduced to 20% in group A and to 0% in group B. Altogether 5 patients with atherosclerotic steno-occlusive CVD remained aspirin-resistant despite the dose escalation; 2 of them suffered an early bypass failure. Smoking habits and diabetes mellitus were positively correlated with aspirin resistance. Moreover, 25% of all patients had laboratory signs of a prothrombotic disorder, but this had no influence on aspirin response or bypass patency. <b><i>Conclusions:</i></b> Aspirin resistance is common in the population of patients with hemodynamic cerebral ischemia scheduled for cerebral revascularization. It may have an adverse impact on the outcome of surgery. Screening and treatment via dose escalation of aspirin is a straightforward and sensible routine for patients undergoing EC-IC bypass surgery." @default.
• W2003146718 created "2016-06-24" @default.
• W2003146718 creator A5006454522 @default.
• W2003146718 creator A5007312538 @default.
• W2003146718 creator A5027480329 @default.
• W2003146718 date "2013-01-01" @default.
• W2003146718 modified "2023-10-03" @default.
• W2003146718 title "Aspirin Resistance in Patients with Hemodynamic Cerebral Ischemia Undergoing Extracranial-Intracranial Bypass Surgery" @default.
• W2003146718 cites W1725209548 @default.
• W2003146718 cites W1796841972 @default.
• W2003146718 cites W1965174960 @default.
• W2003146718 cites W1976292652 @default.
• W2003146718 cites W1979852140 @default.
• W2003146718 cites W1982879251 @default.
• W2003146718 cites W1991721471 @default.
• W2003146718 cites W2009543708 @default.
• W2003146718 cites W2012507663 @default.
• W2003146718 cites W2028882499 @default.
• W2003146718 cites W2035934465 @default.
• W2003146718 cites W2042624073 @default.
• W2003146718 cites W2046066512 @default.
• W2003146718 cites W2054963396 @default.
• W2003146718 cites W2056862930 @default.
• W2003146718 cites W2056905964 @default.
• W2003146718 cites W2058562273 @default.
• W2003146718 cites W2059064084 @default.
• W2003146718 cites W2059871051 @default.
• W2003146718 cites W2073837335 @default.
• W2003146718 cites W2079533463 @default.
• W2003146718 cites W2080716074 @default.
• W2003146718 cites W2093981373 @default.
• W2003146718 cites W2109188310 @default.
• W2003146718 cites W2128630796 @default.
• W2003146718 cites W2135780868 @default.
• W2003146718 cites W2138597449 @default.
• W2003146718 cites W2140261980 @default.
• W2003146718 cites W2140433459 @default.
• W2003146718 cites W2147998031 @default.
• W2003146718 cites W2150230198 @default.
• W2003146718 cites W2156842806 @default.
• W2003146718 cites W2328870579 @default.
• W2003146718 cites W4240019765 @default.
• W2003146718 cites W4366721310 @default.
• W2003146718 doi "https://doi.org/10.1159/000348649" @default.
• W2003146718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23635905" @default.
• W2003146718 hasPublicationYear "2013" @default.
• W2003146718 type Work @default.
• W2003146718 sameAs 2003146718 @default.
• W2003146718 citedByCount "13" @default.
• W2003146718 countsByYear W20031467182015 @default.
• W2003146718 countsByYear W20031467182016 @default.
• W2003146718 countsByYear W20031467182017 @default.
• W2003146718 countsByYear W20031467182018 @default.
• W2003146718 countsByYear W20031467182019 @default.
• W2003146718 countsByYear W20031467182022 @default.
• W2003146718 crossrefType "journal-article" @default.
• W2003146718 hasAuthorship W2003146718A5006454522 @default.
• W2003146718 hasAuthorship W2003146718A5007312538 @default.
• W2003146718 hasAuthorship W2003146718A5027480329 @default.
• W2003146718 hasConcept C126322002 @default.
• W2003146718 hasConcept C141071460 @default.
• W2003146718 hasConcept C164705383 @default.
• W2003146718 hasConcept C178853913 @default.
• W2003146718 hasConcept C2776548475 @default.
• W2003146718 hasConcept C2776820930 @default.
• W2003146718 hasConcept C2777628954 @default.
• W2003146718 hasConcept C2778286760 @default.
• W2003146718 hasConcept C2779433084 @default.
• W2003146718 hasConcept C2779464278 @default.
• W2003146718 hasConcept C2780643987 @default.
• W2003146718 hasConcept C42219234 @default.
• W2003146718 hasConcept C500558357 @default.
• W2003146718 hasConcept C71924100 @default.
• W2003146718 hasConceptScore W2003146718C126322002 @default.
• W2003146718 hasConceptScore W2003146718C141071460 @default.
• W2003146718 hasConceptScore W2003146718C164705383 @default.
• W2003146718 hasConceptScore W2003146718C178853913 @default.
• W2003146718 hasConceptScore W2003146718C2776548475 @default.
• W2003146718 hasConceptScore W2003146718C2776820930 @default.
• W2003146718 hasConceptScore W2003146718C2777628954 @default.
• W2003146718 hasConceptScore W2003146718C2778286760 @default.
• W2003146718 hasConceptScore W2003146718C2779433084 @default.
• W2003146718 hasConceptScore W2003146718C2779464278 @default.
• W2003146718 hasConceptScore W2003146718C2780643987 @default.
• W2003146718 hasConceptScore W2003146718C42219234 @default.
• W2003146718 hasConceptScore W2003146718C500558357 @default.
• W2003146718 hasConceptScore W2003146718C71924100 @default.
• W2003146718 hasIssue "4" @default.
• W2003146718 hasLocation W20031467181 @default.
• W2003146718 hasLocation W20031467182 @default.
• W2003146718 hasOpenAccess W2003146718 @default.
• W2003146718 hasPrimaryLocation W20031467181 @default.
• W2003146718 hasRelatedWork W178629164 @default.
• W2003146718 hasRelatedWork W1976440537 @default.
• W2003146718 hasRelatedWork W2042666779 @default.
• W2003146718 hasRelatedWork W2104536909 @default.
• W2003146718 hasRelatedWork W2202098802 @default.
• W2003146718 hasRelatedWork W2891670898 @default.

• next